title: Safety and efficacy of pegylated liposomal doxorubicin-based adjuvant chemotherapy in patients with stage I-III triple-negative breast cancer.
abstract: OBJECTIVE
  Pegylated liposomal doxorubicin (PLD) has been proven to be an effective antitumor drug for metastatic breast cancer, with less toxicity than conventional anthracycline. Our objective was to evaluate the efficacy and safety of PLD-based adjuvant chemotherapy compared to conventional chemotherapy for patients with stages I-III Triple-negative breast cancer (TNBC).
  
  
  METHODS
  A total of 162 patients, histologically proven to have TNBC at stages I-III between 2003 and 2010, were enrolled to evaluate the impact of PLD- and non-PLD-based adjuvant chemotherapy by using the end-pint of overall survival (OS) and relapse-free survival (RFS).
  
  
  RESULTS
  Forty-nine (30.2%) patients received PLD-based adjuvant chemotherapy and 113 (69.8%) a non-PLD regimen, including 84 (52%) patients receiving non-PLD anthracycline. The Kaplan-Meier calculation indicated no differences in RFS and OS between the PLD and non-PLD groups. Multivariate analysis adjusted for tumor size and lymph node status also revealed similar RFS (HR=0.86, 95% CI=0.43-1.73, p=0.678) and OS (HR=0.86, 95% CI=0.41-1.79, p=0.692) for PLD-based chemotherapy compared with non-PLD-based. Patients receiving PLD-based chemotherapy had a relatively lower incidence of grade 3-4 neutropenia (25% vs. 41.6%, respectively; p=0.054) and significantly higher incidence of hand-foot syndrome (16.3% vs. 4.4%, respectively; p=0.010).
  
  
  CONCLUSIONS
  PLD-based adjuvant chemotherapy was as effective as conventional chemotherapy for patients with TNBC. PLD is an alternative for patients with TNBC when conventional anthracycline is inappropriate.
authors.affiliation: Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, R.O.C.
authors.forename: Ming-Yu
authors.initials: MY
authors.lastname: Lien
authors.affiliation: Department of Surgery, China Medical University Hospital, Taichung, Taiwan, R.O.C.
authors.forename: Liang-Chih
authors.initials: LC
authors.lastname: Liu
authors.affiliation: Department of Surgery, China Medical University Hospital, Taichung, Taiwan, R.O.C.
authors.forename: Hwei-Chung
authors.initials: HC
authors.lastname: Wang
authors.affiliation: Department of Surgery, China Medical University Hospital, Taichung, Taiwan, R.O.C.
authors.forename: Ming-Hsin
authors.initials: MH
authors.lastname: Yeh
authors.affiliation: Department of Surgery, China Medical University Hospital, Taichung, Taiwan, R.O.C.
authors.forename: Chih-Jung
authors.initials: CJ
authors.lastname: Chen
authors.affiliation: Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, R.O.C. Internal Medicine, College of Medicine, China Medical University, Taichung, Taiwan, R.O.C.
authors.forename: Su-Peng
authors.initials: SP
authors.lastname: Yeh
authors.affiliation: Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, R.O.C. Internal Medicine, College of Medicine, China Medical University, Taichung, Taiwan, R.O.C.
authors.forename: Li-Yuan
authors.initials: LY
authors.lastname: Bai
authors.affiliation: Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, R.O.C.
authors.forename: Yu-Min
authors.initials: YM
authors.lastname: Liao
authors.affiliation: Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, R.O.C.
authors.forename: Chen-Yuan
authors.initials: CY
authors.lastname: Lin
authors.affiliation: Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, R.O.C. Graduate Institute of Clinical Medicine, China Medical University, Taichung, Taiwan, R.O.C.
authors.forename: Ching-Yun
authors.initials: CY
authors.lastname: Hsieh
authors.affiliation: Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, R.O.C. Graduate Institute of Clinical Medicine, China Medical University, Taichung, Taiwan, R.O.C.
authors.forename: Ching-Chan
authors.initials: CC
authors.lastname: Lin
authors.affiliation: Graduate Institute of Cancer Biology, China Medical University, Taichung, Taiwan, R.O.C.
authors.forename: Long-Yuan
authors.initials: LY
authors.lastname: Li
authors.affiliation: Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, R.O.C. Department of Medical Genetics, China Medical University Hospital, Taichung, Taiwan, R.O.C. Internal Medicine, College of Medicine, China Medical University, Taichung, Taiwan, R.O.C. Department of Medical Genetics, National Taiwan University Hospital, Taipei, Taiwan, R.O.C. pohanlin01@gmail.com cftl00@gmail.com.
authors.forename: Po-Han
authors.initials: PH
authors.lastname: Lin
authors.affiliation: Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, R.O.C. Internal Medicine, College of Medicine, China Medical University, Taichung, Taiwan, R.O.C. pohanlin01@gmail.com cftl00@gmail.com.
authors.forename: Chang-Fang
authors.initials: CF
authors.lastname: Chiu
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000009:adverse effects* / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D060831:Hand-Foot Syndrome / Q000453:epidemiology; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D009503:Neutropenia / Q000139:chemically induced / Q000453:epidemiology; D011092:Polyethylene Glycols / Q000009:adverse effects / Q000627:therapeutic use; D064726:Triple Negative Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology
chemical_list: D000903:Antibiotics, Antineoplastic; C506643:liposomal doxorubicin; D011092:Polyethylene Glycols; D004317:Doxorubicin
keywords: Pegylated liposomal doxorubicin; adjuvant chemotherapy; anthracycline; triple-negative breast cancer